Drug Profile
RP 01
Alternative Names: RP-01Latest Information Update: 10 Oct 2014
Price :
$50
*
At a glance
- Originator Resistentia Pharmaceuticals
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Immunoglobulin E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis; Peanut hypersensitivity
Most Recent Events
- 09 Oct 2014 Discontinued - Phase-I for Allergic rhinitis in Sweden (Parenteral)
- 09 Oct 2014 Discontinued - Phase-I for Peanut hypersensitivity in Sweden (Parenteral)
- 09 Oct 2014 Discontinued - Phase-II for Allergic asthma in New Zealand (Parenteral)